Alto Neuroscience Bet Big on a Brain Patch. It Didn't Stick.

The trial missed on both.

Now, "missed" in clinical trials doesn't always mean "total disaster." There were some tantalizing near-misses. One EEG measure, called theta-ITC, came in at p=0.052, which is the statistical equivalent of losing by a photo finish. For context, you need p<0.05 for the result to count as statistically significant. Alto was this close but still on the wrong side of the line.

There were also hints that sicker patients (those with worse cognitive impairment) showed directional improvements on EEG, and signals seemed to strengthen between day 5 and day 10 of treatment. Interesting breadcrumbs, but not enough to justify continuing.

On the bright side, the patch did exactly what it was supposed to on the tolerability front. Nausea and vomiting rates were similar to placebo, which is genuinely impressive for a PDE4 inhibitor. Both groups saw skin reactions at the patch site, but that's par for the course with transdermal delivery.

The Pivot: Depression Over Schizophrenia

Rather than throwing more money at ALTO-101 for schizophrenia, Alto is redirecting resources to ALTO-207, a program targeting treatment-resistant depression (TRD). The company hasn't abandoned ALTO-101 entirely; they've developed a modified-release oral version and plan to shop it around to potential partners. Translation: "We still believe in the molecule, but we'd rather someone else take the risk."

It's a pragmatic call. Treatment-resistant depression is a massive market, and ALTO-207's Phase 2b trial is on track to start in the first half of 2026. Alto clearly wants to focus its firepower where the odds look better.

Why Psychiatry Keeps Breaking Hearts

Alto's stumble is part of a much bigger pattern. Developing drugs with novel mechanisms for psychiatric conditions is brutally hard. A recent analysis of 73 clinical trials that led to 16 FDA psychiatric drug approvals between 2013 and 2024 tells a sobering story. Only about 62% of those trials were judged positive by the FDA.

Some approved drugs had shockingly low batting averages. Gepirone, for instance, had just a 17% positive trial rate across its development history. Brexpiprazole came in at 43%. Even drugs that eventually won approval stumbled through more failures than successes on the way there.

The one recent bright spot? KarXT (Cobenfy), a muscarinic agonist approved in September 2024 as the first truly novel schizophrenia drug in over 30 years. But even that success highlighted how long the drought had been. And KarXT targets psychotic symptoms, not cognitive ones, so the CIAS space remains wide open and uncracked.

The core problem is that psychiatric disorders are incredibly heterogeneous. Two people with schizophrenia might share a diagnosis but have completely different underlying biology. It's like trying to find one key that opens a hundred different locks.

Alto's Remaining Hand

Losing ALTO-101 stings, but Alto still has a deep bench of programs in development. ALTO-300, an adjunctive treatment for major depressive disorder, is in a Phase 2b trial with approximately 200 biomarker-positive patients in the final analysis sample and topline data expected by mid-2026. The company ran a favorable interim analysis in early 2025, with an interim cohort of 87 biomarker-positive patients, and expanded the trial to approximately 200 biomarker-positive patients.

ALTO-100, a BDNF enhancer (it promotes brain cell growth and connectivity), is in Phase 2b for bipolar depression. That readout should come in the second half of 2026, partially funded by a roughly $11.7 million convertible loan from Wellcome.

The company's whole thesis rests on precision psychiatry: using EEG biomarkers and machine learning to figure out which patients are most likely to respond to which drugs before they start treatment. That's the kind of edge that could make or break their remaining pipeline.

The Bottom Line

Alto's PDE4 bet didn't pay off, and in the unforgiving world of small-cap biotech, a Phase 2 failure is a serious setback. But the company isn't a one-trick pony. With multiple mid-stage readouts on deck over the next 18 months and a differentiated approach to patient selection, Alto still has shots on goal.

Psychiatry drug development remains one of the hardest games in biotech. The brain doesn't give up its secrets easily, and the clinical trial graveyard is full of molecules that looked promising in early studies. ALTO-101 joins that list. Whether Alto's precision approach can beat those odds with its remaining programs is the question investors will be watching very closely.

A Lung Drug Just Aced a Test It Was Never Built For

United Therapeutics' lung drug Tyvaso just posted blockbuster results in a disease it was never originally designed to treat. The IPF data could double the drug's market, and Wall Street is already doing the math.